GSK has a portfolio of products for major disease areas such as asthma, cancer, infections, mental health, diabetes and digestive conditions. Its drugs and vaccines earned 21.3 billion in 2013; its top-selling products that year were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. The company applied for regulatory approval in 2014 for the first malaria vaccine, RTS,S, which it plans to make available for five percent above cost. Legacy products developed at GSK include albendazole for parasitic infections; amoxicillin, amoxicillin-clavulanate, mupriocin, and trimethoprim for bacterial infections; allopurinol for gout; mercaptopurine and thioguanine for cancer; pyrimethamine for malaria, ranitidine for gastroesophagael reflux disease, and zidovudine for HIV infection, all listed in the World Health Organization Model List of Essential Medicines
GSK’s consumer healthcare products, which earned 5.2 billion in 2013, include Sensodyne and Aquafresh toothpaste, the malted-milk drink Horlicks, Abreva for cold sores, Breathe Right nasal strips, Nicoderm and Nicorette nicotine replacements, and Night Nurse, a cold remedy.